Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Science News discussed open questions in the field with Hursting, Ligibel and health data scientist Jiang Bian of the Indiana University School of Medicine in Indianapolis
Tailored for you Nutrition guidance Support along the way **Based on a 2023 survey by Cerner Enviza of 500 doctors who recommend weight loss programs to patients
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
10.1038/s41591-025-03984-1 Nat Med
US$ 21.69
US$ 21.80
US$ 26.72
US$ 21.26
